Blockchain-based secure data communication and regularization framework for electric vehicle
Elsevier eBooks · 55-74
المخرجات
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
31 output
Elsevier eBooks · 55-74
Elsevier eBooks · 175-186
Elsevier eBooks · 219-240
Elsevier eBooks · 249-271
Advances in computational intelligence and robotics book series · 1-26
This chapter explores the profound impact of artificial intelligence (AI) on pharmaceutical research, particularly focusing on its integration into drug discovery, development, and clinical trial processes. The narrative details how AI-driven methodologies like predictive modeling, virtual screening, and machine learning revolutionize the identification and validation of drug targets and compounds. Additionally, the chapter discusses the application of AI in optimizing clinical trial designs, enhancing patient recruitment, and monitoring trial data in real-time. Ethical considerations including data privacy, bias, and the need for transparency in AI applications are critically analyzed to underscore the necessity for ethical guidelines and regulatory compliance in the evolving landscape of AI-driven pharmaceutical research. The comprehensive overview provided by the authors demonstrates how AI technologies not only accelerate drug development processes but also improve their efficacy, safety, and cost-efficiency.
Elsevier eBooks · 191-223
Elsevier eBooks · 171-196
Elsevier eBooks · 581-614
Advances in computational intelligence and robotics book series · 275-302
Medication adherence remains a significant challenge within healthcare systems globally, especially among groups with chronic illnesses like diabetes, hypertension, and asthma. Despite universally accessible, low-cost Artificial Intelligence (AI) technologies to adherence, an information crevice exists on the utilization of this innovation and its effect on medicine self-efficacy and pharmaceutical adherence in therapeutically underserved populations with an assortment of persistent sicknesses. AI-enabled smartphone applications have surfaced as an encouraging remedy, presenting innovative methods to monitor patient behaviors, verify medication consumption, and deliver personalized reminders. By utilizing real-time monitoring, tailored communication, and behavioral nudges, AI can tackle the various barriers to medication adherence through creative solutions, including forgetfulness, lack of motivation, and insufficient health literacy, while fostering improved health outcomes, particularly among individuals with chronic conditions.
Advances in computational intelligence and robotics book series · 169-188
This chapter discusses the roles of digital biomarkers and artificial intelligence in enhancing precision therapeutics, which is the adaptation of treatments to a person's biomarker patterns for improving an individual's health. Digital biomarkers are collected from wearable technology and other digital devices that record variations in physiological and behavioral indexes thus improving disease diagnosis and treatment. This AI augments these biomarkers' prognostic accuracy and unearths patterns within large datasets within clinical settings; a major change to individualized care. This chapter in the book describes passive and active data acquisition in actual clinical scenarios and offers a conceptual foundation for employing digital biomarkers and artificial intelligence in trials. It also examines diagnostic image analysis and more specifically, the use of MRI to monitor Parkinson's disease, and EEG in managing mental health.
Advances in computational intelligence and robotics book series · 363-376
This chapter provides an overview of the history and impact of artificial intelligence on businesses, with a specific focus on the pharmaceutical industry and research. It discusses the basic principles of pharmacoeconomics, explores ways AI can enhance business processes, and examines various applications of AI in pharmaceutical research, such as drug development, digital therapy, personalized treatment, clinical trials, epidemic forecasting, and supply chain management. The chapter also addresses challenges and considerations related to ethics, safety, data privacy, and liability in AI implementation. Finally, the discussion provides insights into AI's economic opportunities and implications in pharmaceutical research.
Microorganisms for sustainability · 59-77
Microorganisms for sustainability · 129-148
Elsevier eBooks · 75-94
Advances in healthcare information systems and administration book series · 321-350
Healthcare systems in low-income countries face numerous challenges, including limited access to healthcare due to geographical constraints and transport problems, inadequate infrastructure, and a shortage of healthcare professionals. Overworked staff members struggle to meet the growing demand for medical services, and brain drain further exacerbates personnel shortages. Insufficient funding makes healthcare systems difficult to operate, leading to limited budgets for essential services and infrastructure improvements. Financial instability is exacerbated by a high reliance on foreign aid. The burden of preventable and treatable diseases, particularly communicable ones, places a significant strain on limited resources. Lack of health education and policy instability also contribute to these challenges. Inequalities in access to healthcare contribute to social and economic disparities, making it difficult for marginalized communities to obtain adequate medical treatment